INVESTORS
Management and Board
Corporate Governance
Stock Information
Fundamentals
Analysts Coverage
Earnings Estimates
Earnings Ratings
Annual Reports
SEC Filings
Press Releases
Event Calendar
Presentations
Information Request
Investor FAQs
Contact IR

Looking for value? Exelixis is transforming the challenges of biopharmaceutical drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile
We are committed to making a meaningful impact on the lives of patients living with cancer and other serious diseases. In advancing an ambitious and pragmatic approach to drug discovery and development, we intend to develop first-in-class and best-in-class therapies that will transform the treatment of cancer. Exelixis is transforming the challenges of the biotechnology industry into opportunities for success by thinking larger, moving faster and charting our own course to our goal. We have fo... More >>
EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.49
Change (%) Stock is Down 0.1 (1.52%)
Volume915,374
Data as of 05/15/08 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
05/08/08Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care ConferencePrinter Friendly Version
05/06/08Exelixis Announces First Quarter 2008 Financial ResultsPrinter Friendly Version
04/28/08Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference CallPrinter Friendly Version
04/24/08Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged ConferencePrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2007 Annual Report (pdf)
Download Documentation2007 Form 10-K (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.